PharmTech Drug Digest 11.20
|Articles|July 22, 2010

Regulatory Roundup: ICH Draft Residual Solvents Guideline Published; And More.

ICH Draft Residual Solvents Guideline Published; And More.

FDA published this week as a draft recommendation the Step-2 version of the International Conference on Harmonization’s Q3C(R5) Guideline on Residual Solvents to account for new toxicity data related to cumene (Cumol; isopropylbenzene; isopropylbenzol; (1-methyl/ethyl)benzene; 2­Phenylpropane). ICH finalized and approved Q3C(R4), the fourth revision to this guideline, in July 2007. This Step-2 guideline represents a fifth revision, which ICH issued in the form of a final concept paper in June 2009 and approved in March 2010. In Q3C(R4), cumene is listed as a Class-3 solvent in ICH's table of residual solvents. The fifth revision aims to place cumene into Class 2 based on new toxicity data.

 

The Bulk Pharmaceuticals Task Force (BPTF), an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), has released a Quality Agreement template designed for the custom manufacture and release of active pharmaceutical ingredients (APIs). The organization released a general API Quality Agreement Template in May 2010. The templates are meant to help manufacturers, suppliers, and distributors comply with current regulations, including the International Conference on Harmonization Q7 guideline, by putting into place standardized quality agreements.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.